We are live on ! Find out more
PCM

Penserra Capital Management Portfolio holdings

AUM $8.52B
1-Year Est. Return 37.76%
This Fund
S&P 500
This Quarter Est. Return
+4.91%
1 Year Est. Return
+37.76%
3 Year Est. Return
+116.32%
5 Year Est. Return
+122.1%
10 Year Est. Return
+1,892.45%
AUM
$4.68B
AUM Growth
-$145M
Cap. Flow
-$113M
Cap. Flow %
-2.41%
Top 10 Hldgs %
14.09%
Holding
1,671
New
224
Increased
657
Reduced
447
Closed
328

Top Buys

Rank Stock Value
1
MPC icon
Marathon Petroleum
MPC
+$29M
2
NU icon
Nu Holdings
NU
+$25.8M
3
PG icon
Procter & Gamble
PG
+$23.5M
4
NKE icon
Nike
NKE
+$23.1M
5
GRAB icon
Grab
GRAB
+$22.3M

Top Sells

Rank Stock Value
1
JD icon
JD.com
JD
+$44.7M
2
NTES icon
NetEase
NTES
+$40.5M
3
AMD icon
Advanced Micro Devices
AMD
+$37.8M
4
MELI icon
Mercado Libre
MELI
+$33.9M
5
PDD icon
Pinduoduo
PDD
+$33.8M

Sector Composition

Rank Sector Weight
1 Technology 30.82%
2 Consumer Discretionary 19.78%
3 Communication Services 10.14%
4 Financials 6.66%
5 Industrials 6.25%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PCVX icon
1501
Vaxcyte
PCVX
$8.64B
– –
-1,195
Closed -$30K
PGEN icon
1502
Precigen
PGEN
$2.59B
– –
-4,725
Closed -$23K
PGNY icon
1503
Progyny
PGNY
$2.2B
– –
-34,641
Closed -$1.94M
PLRX icon
1504
Pliant Therapeutics
PLRX
$65M
– –
-820
Closed -$13K
PRTA icon
1505
Prothena Corp
PRTA
$450M
– –
-1,030
Closed -$73K
PSNL icon
1506
Personalis
PSNL
$1.51B
– –
-1,015
Closed -$19K
PTCT icon
1507
PTC Therapeutics
PTCT
$6.12B
– –
-1,615
Closed -$60K
PTGX icon
1508
Protagonist Therapeutics
PTGX
$9.44B
– –
-1,090
Closed -$19K
PULS icon
1509
PGIM Ultra Short Bond ETF
PULS
$18.3B
– –
-4,714
Closed -$234K
QNCX icon
1510
Quince Therapeutics
QNCX
$29.5M
– –
-3
Closed -$62K
QURE icon
1511
uniQure
QURE
$3.22B
– –
-1,050
Closed -$33K
RAPT
1512
DELISTED
RAPT Therapeutics
RAPT
– –
-84
Closed -$20K
RCKT icon
1513
Rocket Pharmaceuticals
RCKT
$394M
– –
-1,455
Closed -$43K
RDHL
1514
Redhill Biopharma
RDHL
$3.68M
– –
-1
Closed -$4K
REPL icon
1515
Replimune Group
REPL
$1.01B
– –
-1,070
Closed -$31K
RGEN icon
1516
Repligen
RGEN
$9.25B
– –
-27,989
Closed -$8.09M
RGNX icon
1517
Regenxbio
RGNX
$708M
– –
-975
Closed -$40K
RIGL icon
1518
Rigel Pharmaceuticals
RIGL
$750M
– –
-390
Closed -$14K
RLAY icon
1519
Relay Therapeutics
RLAY
$4.33B
– –
-2,115
Closed -$66K
RLMD icon
1520
Relmada Therapeutics
RLMD
$527M
– –
-400
Closed -$10K
RNAM
1521
DELISTED
Avidity Biosciences
RNAM
– –
-1,040
Closed -$25K
RNAC icon
1522
Cartesian Therapeutics
RNAC
$268M
– –
-88
Closed -$10K
RPTX
1523
DELISTED
Repare Therapeutics
RPTX
– –
-850
Closed -$22K
RSPT icon
1524
Invesco S&P 500 Equal Weight Technology ETF
RSPT
$5.87B
– –
-1,460
Closed -$42K
RVMD icon
1525
Revolution Medicines
RVMD
$44B
– –
-1,690
Closed -$46K
59 60
61
62 63

Similar funds

GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NB
Norinchukin Bank Tokyo, Japan $8.57B AUM 20.17% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
ACM
Advisors Capital Management Ridgewood, New Jersey $8.58B AUM 23.43% 1-Year Est. Return
FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Penserra Capital Management's Q4 2021 Portfolio in Review

As of Q4 2021, Penserra Capital Management held 1,671 positions worth $4.68B, down 3% from $4.82B the previous quarter. Its ten largest holdings account for 14% of the portfolio.

Penserra Capital Management's Q4 2021 filing shows 224 new, 657 increased, 447 reduced and 328 closed positions. Its largest new stake was Marathon Petroleum: 451,379 shares worth $28.9M. The largest sale was JD.com, an estimated $44.7M.

By sector, the portfolio is most concentrated in Technology at 31% of assets, up from 28% a quarter earlier, followed by Consumer Discretionary and Communication Services.

  • Penserra Capital Management's largest Q4 2021 buy was Marathon Petroleum: 451,379 shares worth $28.9M.
  • Penserra Capital Management added most to Procter & Gamble in Q4 2021, an estimated $23.5M increase.
  • Penserra Capital Management's biggest Q4 2021 reduction was JD.com, cutting an estimated $44.7M.
  • Penserra Capital Management fully exited Stamps.com, Inc. in Q4 2021, selling an estimated $32.7M.
  • Penserra Capital Management's ten largest holdings make up 14% of its $4.68B portfolio in Q4 2021.
  • Penserra Capital Management opened 224 new positions and closed 328 in Q4 2021.
  • Penserra Capital Management's portfolio value fell 3% quarter-over-quarter to $4.68B.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.